chronic hepatitis C virus infection
Hepatology · 2014–2018
6decisions
5medicines
5carried consumer input
439individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| grazoprevir with elbasvir Chronic Hepatitis C Virus infection – Genotype 1 or 4 in adults. | Mar 2018 | Deferred | input received Hepatitis Australia |
| sofosbuvir with velpatasvir Treatment of chronic hepatitis C virus infection (all genotypes 1, 2, 3, 4, 5 or 6). | Jul 2017 | Not recommended | none received |
| paritaprevir with ritonavir and ombitasvir Treatment of patients infected with genotype 4 chronic hepatitis C virus infection, irrespective of previous treatment history, in combination with ribavirin. | Nov 2016 | Recommended with restriction | 3 individuals |
| sofosbuvir with velpatasvir Treatment of chronic hepatitis C virus (HCV) infection in adults. | Nov 2016 | Recommended with restriction | 3 individuals |
| daclatasvir Treatment of chronic hepatitis C virus (HCV) infection in combination with sofosbuvir, for patients with all HCV genotypes regardless of previous treatment… | Mar 2015 | Recommended with restriction | 172 individuals Gastroenterological Society |
| simeprevir Chronic hepatitis C virus (HCV) genotype 1 infection, in combination with peginterferon alfa and ribavirin, for treatment-naïve patients and patients… | Jul 2014 | Recommended with restriction | 261 individuals |
Who spoke
Gastroenterological Society · Hepatitis Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.